- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03223051
Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy (ExplorASI)
November 22, 2019 updated by: Centre d'Investigation Clinique et Technologique 805
The aim of this randomized study is to develop a new motor assessment of space exploration in a 2D environment with upper limbs for children with spinal muscular atrophy 1 and 2 from 3 until 16 years old.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Thirty children are included in the prospective randomized study.
They are evaluated with the new test, Space Exploration Test (TES), and with the Motor Function Measure (MFM), a gold standard scale.
The objective is to compare the results and to demonstrate the complementarity of the two tools.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Garches, France, 92380
- Hôpital Raymond Poincaré
-
Garches, France, 92380
- Nicolas ROCHE, Md PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 years to 16 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- children, girls and boys, from 3 to 16 years old,
- with Spinal Motor Atrophy 1 and 2
- with social protection
Exclusion Criteria:
- cognitive disorders preventing understanding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Evaluation
Included patients will be invited to participate in 1 session, to be evaluated with the Motor Function Measure and the new test of space exploration, during 2 hours maximum, to compare scores with these 2 tests. An occupational therapist will be required to install the patient in front of the table and to give the instructions. |
An occupational therapist install the patient sitting in front of the test board and tell him the instructions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motor Function Measure (MFM)
Time Frame: 1 hour
|
Clinical Evaluation
|
1 hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Space Exploration Test (SET)
Time Frame: 20 minutes
|
The SET is made through a test board 170 cm long and 60 cm deep, developed by in our lab
|
20 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Nicolas ROCHE, MDphD, Raymond Poincaré Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 7, 2017
Primary Completion (Actual)
November 22, 2019
Study Completion (Actual)
November 22, 2019
Study Registration Dates
First Submitted
July 18, 2017
First Submitted That Met QC Criteria
July 18, 2017
First Posted (Actual)
July 19, 2017
Study Record Updates
Last Update Posted (Actual)
November 25, 2019
Last Update Submitted That Met QC Criteria
November 22, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-A01017-46
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Muscular Atrophy
-
Marco CapogrossoRoche-GenentechRecruitingSpinal Muscular Atrophy Type 3 | Spinal Muscular Atrophy Type 4United States
-
Institut de Myologie, FranceInstitut RocheCompletedType 2 Spinal Muscular Atrophy | Type 3 Spinal Muscular AtrophyBelgium, France, Germany
-
Marco CapogrossoRoche-GenentechNot yet recruitingSpinal Muscular Atrophy | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy 4United States
-
Novartis Gene TherapiesActive, not recruitingSMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type I | Spinal Muscular Atrophy Type IIIUnited States, Belgium, France, Japan, United Kingdom, Italy, Taiwan, Australia, Canada
-
Hoffmann-La RocheRecruitingSpinal Muscular Atrophy (SMA)Belgium, United States, Croatia, Japan, Netherlands, Spain, Canada, Poland, United Kingdom, Italy, Portugal, Australia
-
Northwell HealthCompletedAdult Spinal Muscular AtrophyUnited States
-
Hugh McMillanFamilies of Spinal Muscular Atrophy; Gwendolyn Strong FoundationTerminatedSpinal Muscular Atrophy (SMA)Canada
-
Hoffmann-La RocheAssociation Française contre les Myopathies (AFM), ParisCompletedSpinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type III Non AmbulantGermany, Italy, France, Belgium, Poland, Netherlands, United Kingdom
-
AveXis, Inc.United BioSource, LLCRecruitingSpinal Muscular Atrophy (SMA)Japan, United States, Korea, Republic of, Israel, Greece, Ireland, Portugal, Russian Federation, Taiwan
-
Istanbul Medipol University HospitalIstanbul UniversityRecruitingNeuromuscular Diseases | Spinal Muscular Atrophy Type 3Turkey
Clinical Trials on Motor assessment
-
Afyonkarahisar Health Sciences UniversityRecruiting
-
National Research Center for Rehabilitation Technical...RecruitingDysphagia | Healthy Volunteers | Motor DeficitsChina
-
University of DelawareNational Institutes of Health (NIH)RecruitingParkinson Disease | Motor ControlUnited States
-
Peking University Third HospitalCompletedCervical Spine MyelopathyChina
-
Gazi UniversityCompleted
-
Great Lakes NeuroTechnologies Inc.National Institute of Nursing Research (NINR)Unknown
-
Helsinki University Central HospitalUniversity of Helsinki; Tampere University; Kamuzu University of Health SciencesRecruitingInfant DevelopmentFinland, Malawi
-
Cliniques universitaires Saint-Luc- Université...UnknownCerebral Palsy | Perceptual Disorders | HemiparesisBelgium
-
Vanderbilt University Medical CenterVanderbilt Institute for Clinical and Translational ResearchCompletedNervous System Diseases | Neurologic Manifestations | Movement Disorders | Neuromuscular Manifestations | Cervical Dystonia | Focal Dystonia | Signs and Symptoms | Spasmodic TorticollisUnited States